

Drug Enforcement Administration

[Docket No. DEA-841]

Importer of Controlled Substances Application: Purisys, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Purisys, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration,
Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement
Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.
All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 6, 2021, Purisys, LLC, 1550 Olympic Drive, Atlanta, Georgia 30601-

1602, applied to be registered as an importer of the following basic class(es) of controlled

substance(s):

Drug Code Schedule Controlled Substance

9668 Noroxymorphone II

The company plans to use as reference standards for analytical and research purposes for

their customers. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is

consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend

to the import of Food and Drug Administration-approved or non-approved finished dosage

forms for commercial sale.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2021-11070 Filed: 5/25/2021 8:45 am; Publication Date: 5/26/2021]